DIXON WENDY L
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Transaction History
| BDTX | ▲ Buy | Grant | 3,253 | $15K | 3/15/2024 | View on chart |
| BDTX | ▲ Buy | Grant | 4,043 | $11K | 12/15/2023 | View on chart |
| BDTX | ▲ Buy | Grant | 2,986 | $11K | 9/15/2023 | View on chart |
| BDTX | ▲ Buy | Grant | 5,119 | $11K | 6/16/2023 | View on chart |
| ARVN | ▲ Buy | Grant | 4,121 | $0 | 6/15/2023 | View on chart |
| BDTX | ▲ Buy | Grant | 6,437 | $11K | 3/16/2023 | View on chart |
| BDTX | ▲ Buy | Grant | 7,167 | $11K | 12/16/2022 | View on chart |
| BDTX | ▲ Buy | Grant | 4,103 | $11K | 9/16/2022 | View on chart |
| BDTX | ▲ Buy | Grant | 4,060 | $8K | 6/17/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 7,585 | — | 6/14/2022 | View on chart |
| INCY | ▲ Buy | Grant | 249 | $20K | 3/31/2022 | View on chart |
| INCY | ▲ Buy | Grant | 260 | $19K | 12/31/2021 | View on chart |
| INCY | ▲ Buy | Option Exercise | 20,000 | $1.5M | 12/23/2021 | View on chart |
| INCY | ▼ Sell | Open Market | 20,000 | $441K | 12/23/2021 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,578 | — | 12/2/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,339 | $30K | 12/2/2021 | View on chart |
| INCY | ▲ Buy | Grant | 244 | $17K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Arvinas Releases Q2 2026 Earnings Call Transcript
Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.
Arvinas Releases Q2 2026 Earnings Call Transcript. Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.